Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

被引：10
|
作者：
Kaisary, AV [1 ]
机构：
[1] Royal Free Hosp, Dept Urol, London NW3 2QG, England
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2005年 / 8卷 / 02期
关键词：
prostate cancer; hormonal therapy; castration; luteinising hormone-releasing hormone agonist; nonsteroidal antiandrogen;
D O I：
10.1038/sj.pcan.4500800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin ('Zoladex') in locally advanced disease. Adjuvant to radical prostatectomy, castration ( goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide ('Casodex') improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration.
引用
收藏
页码：140 / 151
页数：12
相关论文
共 50 条
  • [21] Comorbidity, Use of Common Medications, and Risk of Early Death in Patients with Localized or Locally Advanced Prostate Cancer
    Nieder, Carsten
    Dalhaug, Astrid
    Pawinski, Adam
    Aandahl, Gro
    Norum, Jan
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 1178 - 1186
  • [22] Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review
    Fleshner, Neil E.
    Alibhai, Shabbir M. H.
    Connelly, Kim A.
    Martins, Ilidio
    Eigl, Bernhard J.
    Lukka, Himu
    Aprikian, Armen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [23] Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer
    Langley, Ruth E.
    Godsland, Ian F.
    Kynaston, Howard
    Clarke, Noel W.
    Rosen, Stuart D.
    Morgan, Rachel C.
    Pollock, Philip
    Kockelbergh, Roger
    Lalani, El-Nasir
    Dearnaley, David
    Parmar, Mahesh
    Abel, Paul D.
    BJU INTERNATIONAL, 2008, 102 (04) : 442 - 445
  • [24] ADVANCES AND TRENDS IN HORMONAL-THERAPY FOR ADVANCED PROSTATE-CANCER
    DEBRUYNE, FMJ
    DIJKMAN, GA
    EUROPEAN UROLOGY, 1995, 28 (03) : 177 - 188
  • [25] Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future
    Turco, Fabio
    Buttigliero, Consuelo
    Delcuratolo, Marco Donatello
    Gillessen, Silke
    Vogl, Ursula Maria
    Zilli, Thomas
    Fossati, Nicola
    Gallina, Andrea
    Farinea, Giovanni
    Di Stefano, Rosario Francesco
    Calabrese, Mariangela
    Saporita, Isabella
    Crespi, Veronica
    Poletto, Stefano
    Palesandro, Erica
    Di Maio, Massimo
    Scagliotti, Giorgio Vittorio
    Tucci, Marcello
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [26] Primary hormone therapy for locally advanced prostate cancer
    Swanson G.P.
    Current Urology Reports, 2006, 7 (3) : 225 - 232
  • [27] Radiation therapy in the management of locally advanced prostate cancer
    Michalski J.M.
    Current Urology Reports, 2006, 7 (3) : 217 - 224
  • [28] Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer
    Navon, L
    Morag, A
    SOCIAL SCIENCE & MEDICINE, 2004, 58 (11) : 2337 - 2347
  • [29] Tailoring of hormonal therapy in prostate cancer
    Newling, DWW
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (01) : 21 - 27
  • [30] Tailoring of hormonal therapy in prostate cancer
    DWW Newling
    Prostate Cancer and Prostatic Diseases, 2000, 3 : 21 - 27
12345